Critical Path Institute Announces FDA Commissioner Robert Califf to Participate in Opening Session at Inaugural Global Impact Conference

Critical Path Institute (C-Path) is honored to announce that FDA Commissioner Robert M. Califf, M.D., MACC, will participate as a panelist during the opening session of its inaugural C-Path Global Impact Conference (CGIC) on Monday, September 9, at the Washington Marriott at Metro Center.

“We are thrilled to welcome Commissioner Califf to our annual impact conference underscoring the importance of our shared mission to accelerate drug development across multiple therapeutic areas, including neurology, rare diseases, and pediatrics,” said C-Path CEO Klaus Romero, M.D., M.S., FCP. “With a long history of collaboration with the FDA, our organization has been at the forefront of forming public-private partnerships that drive innovation and address unmet medical needs. Dr. Califf plays a crucial role in this relationship, and we look forward to continuing our work together to advance tools and solutions that will ultimately benefit patients and their families.”

CGIC marks a significant milestone of C-Path’s mission, bringing together leaders from the FDA, EMA, industry, academia, and patient advocacy to foster dialogue and innovation in drug development. The conference will feature presentations and panels focused on integrating insights, advances in regulatory landscapes, and fostering collaborative solutions.

For more information, please visit the event site, here.

About Critical Path Institute

Critical Path Institute (C-Path) is an independent, nonprofit organization established in 2005 as a public and private partnership. C-Path’s mission is to catalyze the development of new approaches that advance medical innovation and regulatory science, accelerating the path to a healthier world. An international leader in forming collaborations, C-Path has established numerous global consortia that currently include more than 1,600 scientists from government and regulatory agencies, academia, patient organizations, disease foundations, and hundreds of pharmaceutical and biotech companies. C-Path U.S. is headquartered in Tucson, Arizona and C-Path in Europe is headquartered in Amsterdam, Netherlands with additional staff in multiple other locations. For more information, visit c-path.org.

Critical Path Institute is supported by the Food and Drug Administration (FDA) of the Department of Health and Human Services (HHS) and is 55% funded by the FDA/HHS, totaling $17,612,250, and 45% funded by non-government source(s), totaling $14,203,111. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, FDA/HHS or the U.S. Government.